Novartis AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 80
- Registration Number
- NCT00434317
- Locations
- 🇭🇺
Novartis Investigative Site, Szekesfehervar, Hungary
Immunogenicity, Safety and Tolerability of Two Doses of FLUAD-H5N1 Influenza Vaccine in Adult and Elderly Subjects
- Conditions
- Influenza
- First Posted Date
- 2007-02-13
- Last Posted Date
- 2008-04-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 4400
- Registration Number
- NCT00434733
- Locations
- 🇵🇱
Centrum Badań Farmakologii Klinicznej monipol, Kraków, Poland
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
- Conditions
- Macular DegenerationChoroidal Neovascularization
- Interventions
- First Posted Date
- 2007-02-09
- Last Posted Date
- 2011-04-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 255
- Registration Number
- NCT00433017
- Locations
- 🇬🇧
Novartis Investigative site, Manchester, United Kingdom
Effects of Zoledronic Acid and Raloxifene on Bone Turnover Markers in Postmenopausal Women With Low Bone Mineral Density
- Conditions
- Osteoporosis
- Interventions
- Drug: Placebo oral pillsDrug: Placebo intravenous (i.v.) infusion
- First Posted Date
- 2007-02-05
- Last Posted Date
- 2011-03-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 110
- Registration Number
- NCT00431444
- Locations
- 🇺🇸
Women's Health Research, Phoenix, Arizona, United States
🇺🇸Alegent Health, Omaha, Nebraska, United States
🇺🇸UMDNJ-Robert Wood Johnson Medical Center, New Brunswick, New Jersey, United States
Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease
- Conditions
- Alzheimer's Disease
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2014-06-11
- Lead Sponsor
- Novartis
- Target Recruit Count
- 262
- Registration Number
- NCT00428389
- Locations
- 🇺🇸
Margolin Brain Institute, Fresno, California, United States
🇺🇸Sunrise Clinical Research, Hollywood, Florida, United States
🇺🇸Premiere Research Institute @ Palm Beach Neurology, West Palm Beach, Florida, United States
Safety and Efficacy of Methylphenidate in Children With Attention-deficit Hyperactivity Disorder (ADHD)
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- First Posted Date
- 2007-01-30
- Last Posted Date
- 2011-05-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00428792
- Locations
- 🇩🇪
Novartis Investigative Site, Freiburg, Germany
Study to Investigate the Effect of Deferasirox on the Pharmacokinetics of Midazolam
- Conditions
- Healthy
- First Posted Date
- 2007-01-29
- Last Posted Date
- 2009-11-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 22
- Registration Number
- NCT00427505
Efficacy and Safety of Diclofenac Sodium Gel (DSG) in Knee Osteoarthritis
- Conditions
- Osteoarthritis of the Knee
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-01-25
- Last Posted Date
- 2007-12-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 420
- Registration Number
- NCT00426621
- Locations
- 🇺🇸
Holston Medical Group, Kingsport, Tennessee, United States
🇺🇸North Carolina Arthritis & Allergy Care Center, Raleigh, North Carolina, United States
🇺🇸Texas Research Center, LLP, Sugar Land, Texas, United States
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients Hypertension
- Conditions
- Hypertension
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis
- Target Recruit Count
- 480
- Registration Number
- NCT00425997
- Locations
- 🇺🇸
Sites in USA, East Hanover, New Jersey, United States
Safety, Efficacy and Pharmacokinetics of Subcutaneous ACZ885 in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
- First Posted Date
- 2007-01-24
- Last Posted Date
- 2011-08-09
- Lead Sponsor
- Novartis
- Target Recruit Count
- 26
- Registration Number
- NCT00426218
- Locations
- 🇮🇹
Novartis Investigative site, Origgio, Italy